M3 Inc is a Japan-based company engaged in providing medical-related services through internet-based platforms and real-world operations. The company operates six reportable segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, Patient Solutions, and Overseas. Its businesses include online marketing for medical professionals, clinical trial support, human resources services for medical professionals, operational support for medical institutions, and patient support services. The Overseas segment offers similar services internationally, including in the United States, the United Kingdom, China, South Korea, India, France, Germany, and Spain.
2000
18.4K+
LTM Revenue $2.2B
LTM EBITDA $544M
$9.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, M3 Inc. reported last 12-month revenue of $2.2B and EBITDA of $544M.
In the same period, M3 Inc. generated $1.1B in LTM gross profit and $294M in net income.
See M3 Inc. valuation multiples based on analyst estimatesIn the most recent fiscal year, M3 Inc. reported revenue of $1.8B and EBITDA of $498M.
M3 Inc. expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See M3 Inc. valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $990M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $544M | XXX | $498M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $453M | XXX | $387M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $294M | XXX | $260M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
M3 Inc. has current market cap of JPY 1.64T (or $10.5B), and EV of JPY 1.50T (or $9.6B).
As of December 3, 2025, M3 Inc.'s stock price is JPY 2420 (or $16).
See M3 Inc. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.6B | $10.5B | XXX | XXX | XXX | XXX | $0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialM3 Inc.'s trades at 5.5x EV/Revenue multiple, and 19.3x EV/EBITDA.
See valuation multiples for M3 Inc. and 15K+ public compsAs of December 3, 2025, M3 Inc. has market cap of $10.5B and EV of $9.6B.
Equity research analysts estimate M3 Inc.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
M3 Inc. has a P/E ratio of 35.8x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.5B | XXX | $10.5B | XXX | XXX | XXX |
| EV (current) | $9.6B | XXX | $9.6B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 17.7x | XXX | 19.3x | XXX | XXX | XXX |
| EV/EBIT | 21.3x | XXX | 24.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.8x | XXX | 39.3x | XXX | XXX | XXX |
| EV/FCF | 49.6x | XXX | 33.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialM3 Inc.'s last 12 month revenue growth is 16%
M3 Inc.'s revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
M3 Inc.'s rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
M3 Inc.'s rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for M3 Inc. and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Apiam Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Artrya | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
M3 Inc. acquired XXX companies to date.
Last acquisition by M3 Inc. was XXXXXXXX, XXXXX XXXXX XXXXXX . M3 Inc. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was M3 Inc. founded? | M3 Inc. was founded in 2000. |
| Where is M3 Inc. headquartered? | M3 Inc. is headquartered in Japan. |
| How many employees does M3 Inc. have? | As of today, M3 Inc. has 18.4K+ employees. |
| Is M3 Inc. publicy listed? | Yes, M3 Inc. is a public company listed on TKS. |
| What is the stock symbol of M3 Inc.? | M3 Inc. trades under 2413 ticker. |
| When did M3 Inc. go public? | M3 Inc. went public in 2004. |
| Who are competitors of M3 Inc.? | Similar companies to M3 Inc. include e.g. Apiam Animal Health, Alcidion Group, Artrya, CurveBeam AI. |
| What is the current market cap of M3 Inc.? | M3 Inc.'s current market cap is $10.5B |
| What is the current revenue of M3 Inc.? | M3 Inc.'s last 12 months revenue is $2.2B. |
| What is the current revenue growth of M3 Inc.? | M3 Inc. revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of M3 Inc.? | Current revenue multiple of M3 Inc. is 4.5x. |
| Is M3 Inc. profitable? | Yes, M3 Inc. is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of M3 Inc.? | M3 Inc.'s last 12 months EBITDA is $544M. |
| What is M3 Inc.'s EBITDA margin? | M3 Inc.'s last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of M3 Inc.? | Current EBITDA multiple of M3 Inc. is 17.7x. |
| What is the current FCF of M3 Inc.? | M3 Inc.'s last 12 months FCF is $195M. |
| What is M3 Inc.'s FCF margin? | M3 Inc.'s last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of M3 Inc.? | Current FCF multiple of M3 Inc. is 49.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.